(Bloomberg) -- Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease ...

Swiss pharma company Roche ... FDA Priority Review status for a Perjeta (pertuzumab) regimen to be used before surgery (neoadjuvant treatment) in people with HER2-positive early stage breast cancer.

ZURICH -- Roche Holding AG (ROG.VX ... closer to the approval of a new personalised medicine for people with this aggressive form of breast cancer," said Hal Barron, Roche's Chief Medical Officer ...

A study involving an experimental cancer drug being developed by Roche Holding (RHHBY, ROG.VX) showed it delayed disease progression in women with a specific type of breast cancer compared to ...

The US Food and Drug Administration has granted a Priority Review ... Roche evaluation its Imlygic (talimogene laherparepvec) in combination with atezolizumab in triple-negative breast cancer ...